

An estimator for correlation between two survival score statistics

Zakiyah Zain
Lancaster University, U.K.

KEY SUMMARY

- Successful work for binary and ordinal, but a challenge for survival.
- Application to logrank is difficult, hence interval censored approach.
- Impact:
 - minimize sample size,
 - facilitate multiple testing procedures
- Objectives:
 - derive an estimator for the correlation
 - investigate properties
 - evaluate accuracy

Interval-censored survival

- Survive past time t ? Yes or No.

Responses during interval (0, t)	Experimental	Control	Total
No. of events (Failure)	o_E	o_C	o
No. of patients survived (Success)	$r_E - o_E$	$r_C - o_C$	$r - o$
Total	r_E	r_C	r

- The log hazard ratio,

$$\theta = -\log\{-\log S_E(t)\} + \log\{-\log S_C(t)\}$$


where S_E is the survivor function of patients on experimental.

$$Z = \frac{q}{o} \{r_E o_C - r_C o_E\} \quad V = \frac{q^2 (r - o) r_C r_E}{o(r - 1)}$$

where $q = -\log(1 - o/r)$.

- For large samples and small θ , $Z \sim N(\theta V, V)$

Bivariate score tests




Estimator for Correlation

- Correlation, $\rho_{12} = C_{12} / \sqrt{V_1 V_2}$
- Covariance derived from cloglog link for uncensored data,

$$C_{12} = \frac{q_1 q_2 r_{1E} r_{1C}}{o_1 o_2 r_1} (r_1 o_{12} - o_1 o_2)$$

where $r_1 = r_2 = r_{12} = n$ (sample size).

Interval-censored bivariate survival

- Without censoring, straightforward..... 

For control		T ₁		
T ₂		Failure	Success	Total
	Failure	FF	SF	O _{2C}
	Success	FS	SS	r _{2C} -O _{2C}
	Total	O _{1C}	r _{1C} -O _{1C}	r _{1C} = r _{2C} = r _{12C}

- With censoring, complication arises..... 

For control		T ₁			
T ₂		Failure	Success	Missing	Total
	Failure	FF	SF	MF	O _{2C}
	Success	FS	SS	MS	r _{2C} -O _{2C}
	Missing	FM	SM	MM	m ₂
Total	O _{1C}	r _{1C} -O _{1C}	m ₁	?	

Interval-censored bivariate survival

double failure, o_{12}		T_1									
		(0, 1)		(1, 3)		(3, 6)		(6, 12)		>12	
treatment		E	C	E	C	E	C	E	C	E	C
T_2	(0, 1)	15	10	5	10	1	2	2	1	0	0
	(1, 3)	18	26	3	10	2	1	6	0	0	0
	(3, 6)	6	2	5	5	1	1	1	2	0	0
	(6, 12)	3	9	2	1	3	2	0	0	0	0
	>12	0	0	0	0	0	0	0	0	0	0

cov(Z_{1i}, Z_{2j})		T_1			Z_{2j}	V_{2j}		
		(0, 1)	(1, 3)	(3, 6)				
T_2	(0, 1)	1.274	1.477	0.137	-1.219	11.482		
	(1, 3)	5.366	0.664	-0.303	1.464	16.275		
	(3, 6)	-0.775	1.469	-0.237	-2.969	5.717		
	(6, 12)	1.103	-0.196	.	0.687	4.917		
	Z_{1i}	9.383	2.654	2.640			$\sum Z_1$	14.676
	V_{1i}	30.515	18.199	7.088			$\sum V_1$	55.802
					$\sum Z_2$	$\sum V_2$	C_{12}	
					-2.037	38.391		9.980

Simulation Study

Distribution

- $T_1 \sim \text{Exp}(\lambda e^s), T_2 \sim \text{Exp}(\lambda e^s),$
- $s \sim N(0, \sigma^2); \sigma = c(\log \lambda_C - \log \lambda_E),$
 $c = 1, 2 \text{ and } 4.$

Theory


- $V^* = k^* n$
- $V^* = \{(u_\alpha + u_\beta) / \theta_R\}^2$
- $\theta_R^2 = 10.51 / k^* n$

Part I

- Generate $n = 1$ million to get k^*
- T_1 and T_2 split into 5 intervals of (0, 1), (1, 3), (3, 6), (6, 12) and (>12) months.


Part II

- Fix $n = 1,000$ to get θ_R
- Run 10,000 replicates under H_0, H_1 to get $\alpha, 1 - \beta,$
 C_{12}, ρ_{C12}
- Compute sample covariance, $\text{Cov}(Z_1, Z_2), \rho_{\text{cov}}$



Case 1: Uncensored


c	H ₀				
	α_1	α_2	α^*	ρ_{C12}	ρ_{Cov}
1	0.026	0.023	0.024	0.014	0.026
2	0.024	0.021	0.024	0.097	0.105
4	0.024	0.024	0.027	0.295	0.329
c	H ₁				
	$1-\beta_1$	$1-\beta_2$	$1-\beta^*$	ρ_{C12}	ρ_{Cov}
1	0.68	0.69	0.93	0.029	0.024
2	0.70	0.70	0.92	0.100	0.103
4	0.59	0.59	0.78	0.295	0.326



- Type I error within 95% CI (0.022, 0.028).
- Accurate power, hence worth including both times; 95% CI (0.089, 0.91).


Case 2: General

- For subjects who are related, e.g. twins, married couples,



where $r_1 \neq r_2 \neq r_{12} \neq n$

c	H ₀				
	α_1	α_2	α^*	ρ_{C12}	ρ_{Cov}
1	0.025	0.024	0.024	0.026	0.021
2	0.024	0.025	0.025	0.097	0.087
4	0.025	0.025	0.025	0.282	0.260
c	H ₁				
	$1-\beta_1$	$1-\beta_2$	$1-\beta^*$	ρ_{C12}	ρ_{Cov}
1	0.60	0.66	0.90	0.031	0.022
2	0.61	0.65	0.87	0.100	0.092
4	0.51	0.53	0.71	0.282	0.267




Case 3: Paired Organs

- For similar physically related parts of a person, e.g. right/left eye or knee or kidney; where $r_1 = r_2 = r_{12}$



c	H_0				
	α_1	α_2	α^*	ρ_{C12}	ρ_{Cov}
1	0.024	0.025	0.026	0.047	0.046
2	0.026	0.025	0.028	0.126	0.140
4	0.026	0.024	0.027	0.332	0.361
c	H_1				
	$1-\beta_1$	$1-\beta_2$	$1-\beta^*$	ρ_{C12}	ρ_{Cov}
1	0.63	0.63	0.89	0.052	0.047
2	0.63	0.63	0.86	0.130	0.128
4	0.52	0.53	0.69	0.330	0.348




- Accurate power, but slightly inflated Type I error.

Case 4: Successive Events

- For recurrent events; e.g. 1st, 2nd seizures ; where $r_1 > r_2 = r_{12}$



c	H_0				
	α_1	α_2	α^*	ρ_{C12}	ρ_{Cov}
1	0.025	0.023	0.009	0.482	0.006
2	0.024	0.026	0.008	0.558	0.043
4	0.024	0.024	0.007	0.708	0.116
c	H_1				
	$1-\beta_1$	$1-\beta_2$	$1-\beta^*$	ρ_{C12}	ρ_{Cov}
1	0.85	0.60	0.91	0.490	0.012
2	0.79	0.50	0.82	0.563	0.055
4	0.60	0.28	0.51	0.708	0.118



- Power is accurate, but type I error rate is too conservative.
- Derived correlation is doubled!**

Conclusions/Further Work

- Guaranteed Type I error rates.
- Achieved accurate power of test.
- Good estimation of ρ_{C12} for bivariate correlated interval censored survival data, *except for successive events*.
- Further work:
 - Overcome inflation of Type I error
 - Resolve issues of ρ_{C12} for successive events
 - Compare with Wei, Lin & Weissfeld method
 - Adjust for covariates

References

- Bolland, K., Whitehead, J., Cobo, E., and Secades, J. J. (2009). Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. *Pharmaceutical Statistics* **8**, 136-149.
- Pocock SJ, Geller NL, and Tsiatis AA. The Analysis of Multiple Endpoints in Clinical Trials. *Biometrics* 1987; **43**: 487-498.
- Wei, L. J., Lin, D.Y. and Weissfeld, L. (1989). Regression Analysis of Multivariate Incomplete Failure Time Data by Modeling Marginal Distributions. *Journal of the American Statistical Association* **84**, 1065-1073.
- Whitehead J. *The Design and Analysis of Sequential Clinical Trials (Revised 2nd Edition)*. Wiley: Chichester, 1997.
- Whitehead J, Bolland K, Branson M, Todd S. Combining binary and ordinal endpoints from clinical trials: a non-GEE approach. *In preparation*.

Thank You

All Results

